Vermeire S, D'Haens G, Baert F, Danese S, et al. Efficacy and Safety of Subcutaneous Vedolizumab in Patients With Moderately to Severely Active Crohn's Disease: Results From the VISIBLE 2 Randomised Trial. J Crohns Colitis 2022;16:27-38.
PMID: 34402887